The efficacy, safety, and stability of tacrolimus 0.03% ointment in treatment of nonsegmental vitiligo

Joint Authors

Yassa, Haidy A.
Mahran, Ayman Muhammad
Abd al-Azim, Najwa Isa

Source

Journal of Current Medical Research and Practice

Issue

Vol. 5, Issue 1 (31 Mar. 2020), pp.41-45, 5 p.

Publisher

Assiut University Faculty of Medicine

Publication Date

2020-03-31

Country of Publication

Egypt

No. of Pages

5

Main Topic

Diseases

Topics

Abstract EN

Background Topical immunoarm adulators have been successfully used as a monotherapy or in combination with other therapeutic modalities in vitiligo treatment.

Topical tacrolimus has been reported to promote melanoblast differentiation and groth.

Additionally, it promotes a favorable environement that enhances the proliferation of melanocytes/ melanoblasts through an interaction with keratinocytes, and thereby repopulating vitigiginous skin lesions.

Aim To detect the effect of tacrolimus ointements in treatment of nonsegmental vitiligo.

Method A total of 35 patients with vitiligo were enrolled in Tacrolimus this randomized placebo-controlled study.

Two vitiliginous patches were chosen in each patient.

The firstt lesion (A) was treated by tacrolimus 0.03% ointment, and the second lesion (B) was treated by panthenol cream as a placebo.

Treatment course was 3 months, and follow-up was done for three extra months.

Vitiliginous patches were assessed at baseline and monthly for 6 months.

Results Moderate to excellent response was observed in 25.7% of lesions A compared with 0% of lesions B (P = 0.002).

Disease duration has a negative effect on therapeutic response.

No adverse effects were noted to tacrolimus ointment except for mild erythema in 6% of the patients.

Coclusion Given its immunomodulatory properties and lack of cutaneous adverse effects, tacrolimus is a potential therapeutic alternative for vitiligo, with an improved benefit-risk ratio.

American Psychological Association (APA)

Abd al-Azim, Najwa Isa& Yassa, Haidy A.& Mahran, Ayman Muhammad. 2020. The efficacy, safety, and stability of tacrolimus 0.03% ointment in treatment of nonsegmental vitiligo. Journal of Current Medical Research and Practice،Vol. 5, no. 1, pp.41-45.
https://search.emarefa.net/detail/BIM-956227

Modern Language Association (MLA)

Abd al-Azim, Najwa Isa…[et al.]. The efficacy, safety, and stability of tacrolimus 0.03% ointment in treatment of nonsegmental vitiligo. Journal of Current Medical Research and Practice Vol. 5, no. 1 (Jan. / Mar. 2020), pp.41-45.
https://search.emarefa.net/detail/BIM-956227

American Medical Association (AMA)

Abd al-Azim, Najwa Isa& Yassa, Haidy A.& Mahran, Ayman Muhammad. The efficacy, safety, and stability of tacrolimus 0.03% ointment in treatment of nonsegmental vitiligo. Journal of Current Medical Research and Practice. 2020. Vol. 5, no. 1, pp.41-45.
https://search.emarefa.net/detail/BIM-956227

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references : p. 45

Record ID

BIM-956227